DocMorris Reports Strong Growth in Prescription Sales for Q3
DocMorris, a well-known online pharmacy, has recently announced an impressive uptick in prescription revenue during the third quarter of 2024. The company reported a growth of 12.2% in local currency from the same period last year, with exciting developments indicating over 25% growth in recent weeks. This remarkable increase is largely influenced by the rising adoption of e-prescriptions, effectively offsetting the decline of traditional paper prescription usage.
Increasing Over-the-Counter Medicine Sales
The company's performance extends beyond prescriptions; DocMorris has also achieved a modest 1.9% growth in over-the-counter (OTC) medicine sales. This accomplishment aligns with the company's dedication to enhancing profitability while ensuring customer needs are met. The convenience of the DocMorris app plays a significant role in this success, enabling users to easily redeem prescriptions and benefit from next-day delivery. This strategic service improvement has attracted a wave of new prescription customers and encouraged repeat purchases.
TeleClinic Service Boosts Revenue
Moreover, DocMorris' TeleClinic service has doubled its revenue this quarter compared to the previous year, marking a critical pillar of its health ecosystem. The company’s operations in various European countries, including Spain, France, and Portugal, have also shown positive momentum, with a notable revenue increase of 7.4% in local currency from last year.
Impressive Overall Revenue Results
Collectively, the Group's external revenue has risen by 4.9% in local currency, amounting to CHF 265.7 million. The number of active customers has also expanded significantly, adding 200,000 new users to reach a total of 10.2 million by the end of September.
Changes in Executive Leadership
In personnel news, Pablo Ros Gomez has been appointed as the new Chief Technology Officer (CTO), effective November 1, 2024. He will be taking over from Madhu Nutakki, who has decided to leave the position after over three years with the company. With his extensive experience within DocMorris' technology and product divisions, Gomez is expected to drive further advancements in the company's technology and data platform.
Logistical Consolidations
In a bid to optimize operations, DocMorris will be shutting down its logistics site in Halle, Germany, by year's end. This strategic move will consolidate the company’s online customer supply chain at its Heerlen center, with plans to phase out the "Zur Rose" brand.
Future Outlook for DocMorris
Looking to the future, DocMorris has reaffirmed its targets for 2024, anticipating a revenue increase of 5 to 10% in external sales, which includes the booming e-prescription services. Additionally, the company projects an adjusted EBITDA around minus CHF 50 million, along with capital expenditures estimated at approximately CHF 30 million. The projections highlight the company's commitment to growth and adaptation in a rapidly evolving marketplace.
Frequently Asked Questions
What drove the increase in DocMorris' prescription sales?
The increase in prescription sales for DocMorris is mainly attributed to the adoption of e-prescriptions, which has significantly accelerated growth.
How did OTC sales perform in Q3?
DocMorris recorded a modest growth of 1.9% in over-the-counter medicine sales during Q3, reflecting their profitability focus.
Who is the new CTO of DocMorris?
Pablo Ros Gomez has been appointed as the new Chief Technology Officer, succeeding Madhu Nutakki.
What changes are happening in logistics for DocMorris?
DocMorris is closing its logistics site in Halle, Germany, and consolidating operations at its Heerlen center.
What are DocMorris' projections for 2024?
DocMorris aims for a 5 to 10% increase in external revenue and expects an adjusted EBITDA around minus CHF 50 million.
